BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30639280)

  • 21. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.
    Morello CM
    Int J Gen Med; 2011; 4():827-35. PubMed ID: 22267935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.
    Heise T; Pieber TR
    Diabetes Obes Metab; 2007 Sep; 9(5):648-59. PubMed ID: 17645556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?
    Hood RC
    Diabetes Technol Ther; 2017 Apr; 19(4):203-205. PubMed ID: 28418731
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
    Hompesch M; Patel DK; LaSalle JR; Bolli GB
    Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic insulin analogs and their use in dogs and cats.
    Gilor C; Graves TK
    Vet Clin North Am Small Anim Pract; 2010 Mar; 40(2):297-307. PubMed ID: 20219490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin glargine: long-acting basal insulin analog for improved metabolic control.
    Gerich JE
    Curr Med Res Opin; 2004 Jan; 20(1):31-7. PubMed ID: 14741069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of breast cancer by individual insulin use: an international multicenter study.
    Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
    Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current concept of insulin therapy intensification, and the role of human regular insulin and rapid-acting insulin analogs in insulin treatment].
    Hamaguchi T; Sadahiro K; Satoh T
    Nihon Rinsho; 2015 Mar; 73(3):447-52. PubMed ID: 25812371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New insulin analogues.
    Garg SK
    Diabetes Technol Ther; 2005 Oct; 7(5):813-7. PubMed ID: 16241890
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The past, present, and future of basal insulins.
    Pettus J; Santos Cavaiola T; Tamborlane WV; Edelman S
    Diabetes Metab Res Rev; 2016 Sep; 32(6):478-96. PubMed ID: 26509843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New insulin types in type 1 diabetes mellitus].
    Mesa J
    Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs.
    Bolli GB; Porcellati F; Lucidi P; Fanelli CG; Owens DR
    Metabolism; 2022 Jan; 126():154935. PubMed ID: 34762931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addressing hyperglycemia from hospital admission to discharge.
    Moghissi ES
    Curr Med Res Opin; 2010 Mar; 26(3):589-98. PubMed ID: 20078323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Insulin analogs: structure, properties and therapeutic indication. Part 2. Long-acting insulin analogs].
    Rosak C
    Internist (Berl); 2001 Dec; 42(12):1692-9. PubMed ID: 11793609
    [No Abstract]   [Full Text] [Related]  

  • 39. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.
    Reynolds NA; Wagstaff AJ
    Drugs; 2004; 64(17):1957-74. PubMed ID: 15329046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin analogues in the management of diabetes.
    Vázquez-Carrera M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2004; 26(6):445-61. PubMed ID: 15349139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.